“You can see and feel a buzz within the company right now,” said Andrew Stewart, President, Global Pharmaceuticals and International Consumer, at Bausch + Lomb.
Bausch + Lomb’s current momentum stems not only from new leadership, but also from recent collaborations, partnerships, and acquisitions.
Stewart and Yehia Hashad, MD, Executive Vice President of Research & Development and Chief Medical Officer, join host Paul Karpecki, OD, to discuss these activities. Miebo, the first-in-class dry eye asset for the treatment of evaporative dry eye, tops the list.
Looking ahead, Stewart and Dr. Hashad said the company is lasering its focus to tackle more unmet medical needs in eye care. The company intends to build on its legacy of innovation in drug delivery, in MOAs, and in developing new molecular entities.
What’s next for the most recognized name in eye care?
Topics discussed include:
Resources
Miebo https://www.miebo.com
Andrew Stewart https://www.bausch.com/about-bausch-lomb/leadership-team
Yehia Hashad, MD https://www.bausch.com/about-bausch-lomb/leadership-team
Paul Karpecki, OD https://ois.net/paul-karpecki-od